Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 66
1.
HNO ; 63(11): 758-67, 2015 Nov.
Article De | MEDLINE | ID: mdl-26507715

A significantly increasing proportion of oropharyngeal head and neck carcinomas (OSCC) in North America and Europe are associated with human papillomavirus (HPV) infections. HPV-related OSCC is regarded as a distinct tumor type with regard to its cellular, biologic, and clinical characteristics. Patients with HPV-related OSCC have significantly better local control, but higher rates of regional lymph node and distant metastases as compared to patients with HPV-negative OSCC. Classical molecular genetic investigations demonstrated specific chromosomal aberration signatures in HPV-related OSCC, and recent developments in next generation sequencing (NGS) technology have rendered possible the sequencing of entire genomes, and thus detection of specific mutations, in just a few days. Initial data from The Cancer Genome Atlas (TCGA) project obtained by using genome-wide high throughput methods have confirmed that HPV-related OSCC contain fewer, albeit more specific mutations than HPV-negative tumors. Additionally, these data revealed the presence of specific-potentially therapeutically targetable-activating driver mutations in subgroups of HPV-positive OSCC, some of which have a prognostic impact. Specific targeted NGS technologies provide new possibilities for identification of diagnostic, prognostic, and predictive biomarkers and the development of personalized cancer treatment. Patients with HPV-positive tumors are likely to profit from these developments in the future, since the genetic alterations are relatively homogenous and frequently lead to signal pathway activation. There is an urgent need for network research activities to carry out the necessary basic research in prospective cohort studies.


Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/genetics , Papillomavirus Infections/epidemiology , Papillomavirus Infections/genetics , Polymorphism, Single Nucleotide/genetics , Precancerous Conditions/genetics , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Female , Genetic Markers/genetics , Genetic Predisposition to Disease/epidemiology , Genetic Predisposition to Disease/genetics , Genome, Human/genetics , Germany/epidemiology , Humans , Incidence , Male , Middle Aged , Mutation/genetics , Precancerous Conditions/epidemiology , Risk Factors , Sex Distribution , Young Adult
2.
Biomed Microdevices ; 11(3): 685-92, 2009 Jun.
Article En | MEDLINE | ID: mdl-19169825

We have established a fast PCR-based micro flow-through process consisting of a helical constructed tube reactor. By this approach we can detect transcripts of measles and human papilloma virus (HPV) by continuous flow allowing for reverse transcription (RT) and amplification of cDNA. The micro reaction system consisted of two columnar reactors for thermostating the different reaction zones of the RT process and the amplification. The PCR reactor was built by asymmetric heating sections thus realizing different residence times and optimal conditions for denaturation, annealing and elongation. The system concept is based on low electrical power consumption (50-120 W) and is suited for portable diagnostic applications. The samples were applied in form of micro fluidic segments with single volumes between 65 and 130 nL injected into an inert carrier liquid inside a Teflon FEP tube with an inner diameter of 0.5 mm. Optimal amplification for template lengths of 292 bp (lambda-DNA), 127 bp (measles virus) and 95 bp (HPV) was achieved by maximal cycle times of 75 s.


Bacteriophage lambda/genetics , Bioreactors , Human papillomavirus 16/genetics , Measles/genetics , Polymerase Chain Reaction/instrumentation , Bacteriophage lambda/pathogenicity , Cell Line, Tumor , Equipment Design , Female , Human papillomavirus 16/pathogenicity , Humans , Nucleic Acid Amplification Techniques , Polymerase Chain Reaction/methods , Reverse Transcriptase Polymerase Chain Reaction/instrumentation , Reverse Transcriptase Polymerase Chain Reaction/methods , Temperature , Time Factors , Transcription, Genetic
3.
Opt Commun ; 281(7): 1796-1805, 2008 Apr 01.
Article En | MEDLINE | ID: mdl-18496597

Simultaneous spatial and temporal focusing (SSTF), when combined with nonlinear microscopy, can improve the axial excitation confinement of wide-field and line-scanning imaging. Because two-photon excited fluorescence depends inversely on the pulse width of the excitation beam, SSTF decreases the background excitation of the sample outside of the focal volume by broadening the pulse width everywhere but at the geometric focus of the objective lens. This review theoretically describes the beam propagation within the sample using Fresnel diffraction in the frequency domain, deriving an analytical expression for the pulse evolution. SSTF can scan the temporal focal plane axially by adjusting the GVD in the excitation beam path. We theoretically define the axial confinement for line-scanning SSTF imaging using a time-domain understanding and conclude that line-scanning SSTF is similar to the temporally-decorrelated multifocal multiphoton imaging technique. Recent experiments on the temporal focusing effect and its axial confinement, as well as the axial scanning of the temporal focus by tuning the GVD, are presented. We further discuss this technique for axial-scanning multiphoton fluorescence fiber probes without any moving parts at the distal end. The temporal focusing effect in SSTF essentially replaces the focusing of one spatial dimension in conventional wide-field and line-scanning imaging. Although the best axial confinement achieved by SSTF cannot surpass that of a regular point-scanning system, this trade-off between spatial and temporal focusing can provide significant advantages in applications such as high-speed imaging and remote axial scanning in an endoscopic fiber probe.

4.
Indian J Med Microbiol ; 26(1): 13-20, 2008.
Article En | MEDLINE | ID: mdl-18227591

PURPOSE: Molecular genotyping relies on the identification of specific microbial DNA sequences. Accurate genotyping not only requires discrimination between low- and high-risk pathogens for effective diagnosis or disease management but also requires the identity of the specific strain or type of the microbe involved in pathogenesis. The majority of these assays require DNA amplification followed by genome identification either through sequencing or hybridization to specific oligonucleotide probes. We evaluated the use of a DNA microchip assay as a simple and easy-to-use procedure for genotyping. METHODS: Various methodological parameters were optimized for single-base mismatch discrimination on a DNA microarray. The fabrication procedures involved substrate chemistry for immobilization. The effect of various buffers and features associated with oligonucleotide sequences were standardized. The assay was evaluated on a low-density genotyping chip containing the sequences of various (Human Papilloma Virus) HPV subtypes. RESULTS: The specific subtype was identified with high specificity by hybridization in miniaturized condition. CONCLUSIONS: The DNA microchip provides a rapid and cost-effective genotyping procedure for microbial organisms and can be implemented easily in any laboratory.


Molecular Diagnostic Techniques/methods , Oligonucleotide Array Sequence Analysis/methods , Papillomaviridae/classification , Papillomaviridae/isolation & purification , Papillomavirus Infections/diagnosis , Papillomavirus Infections/virology , Genotype , Humans , Molecular Diagnostic Techniques/standards , Oligonucleotide Array Sequence Analysis/standards , Sensitivity and Specificity
5.
Oncogene ; 27(6): 865-76, 2008 Jan 31.
Article En | MEDLINE | ID: mdl-17653090

Inter-alpha-trypsin inhibitors (ITIs) are protease inhibitors stabilizing the extracellular matrix. ITIs consist of one light (bikunin) and two heavy chains (ITIHs). We have recently characterized ITIH5, a novel member of the ITIH gene family, and showed that its messenger RNA is lost in a high proportion of breast tumours. In the present study, an ITIH5-specific polyclonal antibody was generated, validated with western blot and used for immunohistochemical analysis on a tissue microarray; ITIH5 was strongly expressed in epithelial cells of normal breast (n=11/15), while it was lost or strongly reduced in 42% (92/217) of invasive breast cancers. ITIH5 expression in invasive carcinomas was associated with positive expression of oestrogen receptor (P=0.008) and histological grade (P=0.024). Correlation of ITIH5 expression with clinical outcome revealed that patients with primary tumours retaining abundant ITIH5 expression had longer recurrence-free survival (RFS; P=0.037) and overall survival (OS; P=0.044), compared to those with reduced expression (mean RFS: 102 vs 78 months; mean OS: 120 vs 105 months). Methylation-specific PCR analysis frequently showed strong methylation of the ITIH5 promoter in primary breast tumours (41%, n=109) and breast cancer cell lines (n=6). Methylation was significantly associated with mRNA loss (P<0.001; n=39), and ITIH5 expression was induced after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Moreover, ITIH5 promoter methylation was significantly associated with reduced OS (P=0.008). The cellular function of ITIH5 was evaluated by forced expression of a full-length ITIH5 complementary DNA in the breast cancer cell line MDA-MB-231, which does not endogenously express ITIH5. ITIH5-expressing clones showed a 40% reduced proliferation rate compared to mock-transfected cells. Overall, these data show that promoter methylation-mediated loss of ITIH5 expression is associated with unfavourable outcome in breast cancer patients, and thus ITIH5 could be used as a prognostic marker, although this marker is not multivariate independent due to its close association with ER expression. Our data indicate that ITIH5 is a candidate class II tumour suppressor gene and could be involved in tumour progression, invasion and metastasis, as its absence is associated with increased proliferation rates and a prognostic value indicating poor clinical outcome.


Biomarkers, Tumor/genetics , Breast Neoplasms/diagnosis , Carcinoma/diagnosis , DNA Methylation , Proteinase Inhibitory Proteins, Secretory/genetics , Antibodies/metabolism , Biomarkers, Tumor/analysis , Biomarkers, Tumor/metabolism , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Carcinoma/mortality , Carcinoma/pathology , Down-Regulation , Extracellular Matrix/metabolism , Female , Humans , Neoplasm Invasiveness , Prognosis , Promoter Regions, Genetic , Proteinase Inhibitory Proteins, Secretory/analysis , Proteinase Inhibitory Proteins, Secretory/metabolism , RNA, Messenger/analysis , RNA, Messenger/metabolism
6.
Oncogene ; 27(11): 1610-7, 2008 Mar 06.
Article En | MEDLINE | ID: mdl-17828299

Virus integration into the host genome is a characteristic step during cervical carcinogenesis. Experimental data provide evidence that integration could result in increased levels of oncogene (E6/E7) transcripts. This is the first study in which the level of viral transcripts is correlated to the physical state of the viral genome in cervical intraepithelial neoplasia (CIN) and cervical carcinomas (CxCa). Using the APOT-assay integrate-derived transcripts only were detected in 3/28 (11%) CIN and in 28/55 (51%) carcinomas, respectively. The remaining biopsies contained either episome-derived transcripts only or both mRNA species. SybrGreen real time reverse transcriptase-PCR assays were used to quantify viral gene expression for (i) all transcripts initiated from p97, (ii) full-length E6, (iii) E6*I and (iv) E5 transcripts. E6/E7 transcript levels showed a broad distribution but similar median values irrespective of histopathological grading and physical state of the viral genome. Biopsies with integrate-derived transcripts only generally lacked E5-specific mRNA. Our data do not support the hypothesis that HPV integration invariably results in high levels of oncogene transcripts. Instead, constitutive expression of oncogene transcripts rather than the level of expression appears to be decisive for transformation and the maintenance of the malignant phenotype.


Genome, Viral , Human papillomavirus 16/genetics , Oncogene Proteins, Viral/genetics , Papillomavirus Infections/virology , Repressor Proteins/genetics , Uterine Cervical Dysplasia/virology , Uterine Cervical Neoplasms/virology , Virus Integration , DNA, Viral/genetics , DNA, Viral/metabolism , Female , Humans , Oncogene Proteins, Viral/metabolism , Papillomavirus E7 Proteins , Papillomavirus Infections/genetics , Papillomavirus Infections/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Viral/genetics , RNA, Viral/metabolism , Repressor Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/metabolism , Uterine Cervical Dysplasia/genetics , Uterine Cervical Dysplasia/metabolism
7.
Oncogene ; 25(44): 5953-9, 2006 Sep 28.
Article En | MEDLINE | ID: mdl-16636661

The oncoprotein E7 of human papilloma viruses (HPV) is involved in the pathogenesis and maintenance of human cervical cancers. The most prevalent HPV types found in cervix carcinomas are HPV16, 18 and 45. The structure of the E7 dimer from HPV45 (PDB 2F8B) was determined by nuclear magnetic resonance spectroscopy. Each monomer comprises an unfolded N-terminus and a well-structured C-terminal domain with a beta1beta2alpha1beta3alpha2 topology representing a unique zinc-binding fold found only for E7. Dimerization occurs through the alpha1/alpha1' helices and intermolecular beta-sheet formation but excludes the zinc-binding sites. E7 is reported to interact with a number of cellular proteins (e.g. pRb, p21(CIP1)). Binding of a peptide derived from the C-terminus of p21(CIP1) to the C-terminal domain of E7 was characterized by monitoring chemical shift perturbations of the amide groups of E7. This provides direct evidence that a shallow groove situated between alpha1 and beta1 of the E7 C-terminal domain is interacting with the C-terminus of p21(CIP1). Intriguingly, this binding site overlaps with the low-affinity binding site on E7 for the C-domain of pRb.


Oncogene Proteins, Viral/chemistry , Papillomaviridae/chemistry , Papillomavirus E7 Proteins/chemistry , Protein Folding , Amino Acid Sequence , Cyclin-Dependent Kinase Inhibitor p21/chemistry , Dimerization , Humans , Magnetic Resonance Spectroscopy , Molecular Sequence Data , Oncogene Proteins, Viral/genetics , Oncogene Proteins, Viral/isolation & purification , Papillomavirus E7 Proteins/genetics , Papillomavirus E7 Proteins/isolation & purification , Risk Factors , Solutions , Zinc Fingers
8.
Oncogene ; 25(24): 3479-88, 2006 Jun 08.
Article En | MEDLINE | ID: mdl-16449975

The canonical Wnt signalling pathway plays a key role during embryogenesis and defects in this pathway have been implicated in the pathogenesis of various types of tumours, including breast cancer. The gene for secreted frizzled-related protein 1 (SFRP1) encodes a soluble Wnt antagonist and is located in a chromosomal region (8p22-p12) that is often deleted in breast cancer. In colon, lung, bladder and ovarian cancer SFRP1 expression is frequently inactivated by promoter methylation. We have previously shown that loss of SFRP1 protein expression is a common event in breast tumours that is associated with poor overall survival in patients with early breast cancer. To investigate the cause of SFRP1 loss in breast cancer, we performed mutation, methylation and expression analysis in human primary breast tumours and breast cell lines. No SFRP1 gene mutations were detected. However, promoter methylation of SFRP1 was frequently observed in both primary breast cancer (61%, n=130) and cell lines analysed by methylation-specific polymerase chain reaction (MSP). We found a tight correlation (P<0.001) between methylation and loss of SFRP1 expression in primary breast cancer tissue. SFRP1 expression was restored after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Most interestingly, SFRP1 promoter methylation was an independent factor for adverse patient survival in Kaplan-Meier analysis. Our results indicate that promoter hypermethylation is the predominant mechanism of SFRP1 gene silencing in human breast cancer and that SFRP1 gene inactivation in breast cancer is associated with unfavourable prognosis.


Breast Neoplasms/genetics , DNA Methylation , Gene Expression Regulation, Neoplastic , Gene Silencing , Glycoproteins/genetics , Adult , Aged , Aged, 80 and over , Breast Neoplasms/metabolism , Cell Line, Tumor , Epigenesis, Genetic , Female , Humans , Intracellular Signaling Peptides and Proteins , Middle Aged , Wnt Proteins/metabolism
9.
Eur J Cancer ; 39(5): 698-707, 2003 Mar.
Article En | MEDLINE | ID: mdl-12628851

Oncogenic human papillomavirus (HPV) plays a possible aetiological role in a subset of head and neck cancers, particularly in tonsillar carcinomas. For establishing a model to study mechanisms involved in HPV-associated tonsillar carcinogenesis, normal human tonsillar epithelial (HTE) cells were transfected with full-length HPV-16 DNA. The transfections produced four immortalised cell lines, designated HTE-114/K1, HTE-114/K2, HTE-114/K3 and HTE-114/B. All transfected HTE cell lines were cytogenetically abnormal. They exhibited altered morphology and impaired expression of cytokeratins in organotypic cultures. They failed to form colonies in soft agarose and formed no tumours in nude mice within 6 months. Each of them contained integrated viral DNA in a distinctive pattern as shown by Southern blot hybridisation. Early viral transcripts containing the E7 gene were detected by northern blot hybridisation. In conclusion, primary HTE cells can be immortalised following transfection with full-length HPV-16 DNA; the immortalised cell lines had partially retained epithelial characteristics in their morphology and function. They seem to represent early stages of premalignant epithelial cells and thus provide a useful model for studying further the multistep molecular events of HPV-16-associated tonsillar carcinogenesis.


Papillomaviridae , Tonsillar Neoplasms/pathology , Tumor Cells, Cultured/pathology , Tumor Virus Infections/pathology , Animals , Blotting, Northern , Blotting, Southern , Cell Transformation, Neoplastic/pathology , DNA, Viral/analysis , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Mice , Mice, Nude , Papillomaviridae/genetics , Tonsillar Neoplasms/genetics , Tonsillar Neoplasms/virology , Transfection , Tumor Cells, Cultured/virology , Tumor Virus Infections/genetics
10.
Zentralbl Gynakol ; 124(11): 511-24, 2002 Nov.
Article En | MEDLINE | ID: mdl-12796844

Association of infection with papillomavirus and dysplasia of the cervix uteri has been firmly established. There are only few cervical cancers where no HPV DNA is detectable. The mechanism of epithelial cell immortalization by interaction with tumour suppressor genes p53 and pRb by viral oncogenes E6 and E7 is elucidated. Progression of the HPV infected cell to a malignant phenotype involves further modification of host gene expression and/or mutations. The appearance of chromosomal aberrations can lead to mutational inactivation or loss of tumour suppressor genes (TSG), activation and amplification of oncogenes, with importance for the process of carcinogenesis. Oncogene amplification, with exception of few reports, seems not to be a major mechanism in cervical carcinogenesis. In contrast, cytogenetic and loss of heterozygosity (LOH) results from CIN and invasive cancer demonstrate alterations at specific chromosomal regions, pointing at localisation of TSG. Genetic alterations at chromosomes 3p, 6p, 1lq were frequently found early in tumour development Primary invasive carcinoma showed additional allelic losses at chromosome arms 6q, 17p and 18q. Useful biological diagnostic and prognostic markers for high-risk HPV infection and malignant progression may be p16NK4 p27Kip, and NET-I/C4.8. Putative senescence genes relevant for HPV-induced carcinogenesis are localized on chromosomes 2, 4 and 10. Genes for Telomerase suppression are presumably located on chromosomes 3, 4 and 6. Natural immune responses to HPV infection exist Therefore, immune therapy is an attractive possibility for prevention and therapy of HPV infection. To date, vaccine development has reached clinical evaluation. Prophylaxis aims at the induction of virus neutralizing antibodies to capsid proteins. Virus-like particle vaccines are currently tested in clinical trials. Due to the long lag period between infection and clinical manifestation trials will take a long time until conclusive results are obtained. Mandatory expression of viral and perhaps certain cellular genes in infected epithelial and tumour cells offers targets for therapeutic approaches. Since most dysplasia clears spontaneously the viral infection is immunogenic to some extent. However, in some individuals the immune response has to be stimulated by vaccination in order to be effective. Several strategies are being tested in clinical trials and others are in preclinical development The task will be to circumvent immunosuppressive features of the HPV infected cells.


Papillomaviridae , Papillomavirus Infections/physiopathology , Papillomavirus Vaccines , Tumor Virus Infections/physiopathology , Uterine Cervical Neoplasms/virology , Viral Vaccines , Chromosome Mapping , Female , Humans , Loss of Heterozygosity , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/immunology
11.
Nucleic Acids Res ; 29(22): E112, 2001 Nov 15.
Article En | MEDLINE | ID: mdl-11713332

High density oligonucleotide arrays have been used extensively for expression studies of eukaryotic organisms. We have designed a prokaryotic high density oligonucleotide array using the complete Escherichia coli genome sequence to monitor expression levels of all genes and intergenic regions in the genome. Because previously described methods for preparing labeled target nucleic acids are not useful for prokaryotic cell analysis using such arrays, a mRNA enrichment and direct labeling protocol was developed together with a cDNA synthesis protocol. The reproducibility of each labeling method was determined using high density oligonucleotide probe arrays as a read-out methodology and the expression results from direct labeling were compared to the expression results from the cDNA synthesis. About 50% of all annotated E.coli open reading frames are observed to be transcribed, as measured by both protocols, when the cells were grown in rich LB medium. Each labeling method individually showed a high degree of concordance in replica experiments (95 and 99%, respectively), but when each sample preparation method was compared to the other, approximately 32% of the genes observed to be expressed were discordant. However, both labeling methods can detect the same relative gene expression changes when RNA from IPTG-induced cells was labeled and compared to RNA from uninduced E.coli cells.


Adenosine Triphosphate/analogs & derivatives , Oligonucleotide Array Sequence Analysis/methods , RNA, Bacterial/isolation & purification , Adenosine Triphosphate/metabolism , Biotin/metabolism , DNA, Complementary/genetics , Escherichia coli/drug effects , Escherichia coli/genetics , Gene Expression Regulation, Bacterial/drug effects , Genome, Bacterial , Isopropyl Thiogalactoside/pharmacology , Lac Operon/genetics , Nucleic Acid Hybridization/methods , RNA, Bacterial/genetics
12.
Cancer Res ; 61(19): 7118-21, 2001 Oct 01.
Article En | MEDLINE | ID: mdl-11585743

High-risk human papillomavirus (HPV) types 16 and 18 are involved in the multistep process of cervical cancer. Transfection of normal keratinocytes with high-risk HPV-DNA generally gives rise to immortal cultures. This may be explained by the loss of senescence genes as a consequence of HPV-induced genetic instability. On the basis of the dominance of cellular senescence over immortality, fusion of normal keratinocytes with HPV-immortalized cells results in complementation of these putative gene defects. In a previous study, we showed that underrepresentation of chromosome 10 is a characteristic phenomenon during the early phase of immortalization. Here we show that introduction of a normal copy of chromosome 10 into HPV16-immortalized cells (HPKII) by Microcell-mediated chromosome transfer resulted in senescence of a significant number of hybrids. By using several derivatives of chromosome 10 for further fusion experiments, the chromosomal region responsible for senescence could be assigned to 10p14-p15. The potential significance of loss of gene function in this region is underlined by the high frequency (38.7%) of loss of heterozygosity in cervical cancers including early stage tumors.


Cellular Senescence/genetics , Chromosomes, Human, Pair 10/genetics , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/virology , Cell Line, Transformed , Cell Transformation, Viral , Chromosome Mapping , DNA, Viral/genetics , Female , Gene Deletion , Gene Transfer Techniques , Humans , Keratinocytes/cytology , Keratinocytes/physiology , Keratinocytes/virology , Loss of Heterozygosity , Papillomaviridae/genetics , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/virology , Uterine Cervical Dysplasia/genetics , Uterine Cervical Dysplasia/pathology , Uterine Cervical Dysplasia/virology
13.
Electrophoresis ; 22(14): 2898-902, 2001 Aug.
Article En | MEDLINE | ID: mdl-11565785

DNA chip technologies are the most exiting genomic tools, which were developed within the last few years. It is, however, evident that knowledge of the gene sequence or the quantity of gene expression is not sufficient to predict the biological nature and function of a protein. This can be particularly important in cancer research where post-translational modifications of a protein can specifically contribute to the disease. To address this problem, several proteomic tools have been developed. Currently the most widely used proteomic tool is two-dimensional protein gel electrophoresis (2-DE), which can display protein expression patterns to a high degree of resolution. As an alternative to 2-DE, a preliminary study using a new technique was employed to generate protein expression patterns from whole tissue extracts. Surface-enhanced laser desorption/ionization (SELDI) allows the retention of proteins on a solid-phase chromatographic surface (ProteinChip Array) with direct detection of retained proteins by time of flight-mass spectrometry (TOF-MS). Using this system, we analyzed eight cases of renal cell carcinoma (RCC) including normal, peripheral and central tumor tissue as well as four microdissected cases of cervical intraepithelial neoplasia (CIN) and three microdissected cases of cervix uteri carcinoma. Differentially expressed proteins were found by comparing the protein expression patterns generated using SELDI-based TOF-MS of tumor tissue with normal and neoplastic tissue, respectively. By applying this fast and powerful ProteinChip array technology it becomes possible to investigate complex changes at the protein level in cancer associated with tumor development and progression.


Neoplasm Proteins/analysis , Oligonucleotide Array Sequence Analysis , Proteome , Sequence Analysis, Protein/instrumentation , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Carcinoma, Renal Cell/chemistry , Carcinoma, Squamous Cell/chemistry , Data Collection , Electrophoresis, Gel, Two-Dimensional , Female , Humans , Kidney Neoplasms/chemistry , Micromanipulation , Sequence Analysis, Protein/methods , Uterine Cervical Neoplasms/chemistry , Uterine Cervical Dysplasia/chemistry
14.
J Mol Med (Berl) ; 79(5-6): 283-8, 2001 Jun.
Article En | MEDLINE | ID: mdl-11485021

Mutations of the p53 gene have been shown to be associated with aggressive growth behavior and increased recurrence rates for certain tumors. Primary cervical cancers contain oncogenic human papillomaviruses (HPV) in more than 90% of cases and usually possess wild-type p53 alleles. Cervical cancer cells contain detectable levels of functional p53 protein despite of the expression of the HPV E6 protein, which can induce p53 degradation. Thus, inactivation of p53 by somatic mutation should have functional consequences in HPV-positive cancers. We investigated whether p53 mutations play a role in the recurrence of the disease by analyzing p53 status in 18 biopsy specimens from recurrent cervical cancers. Only one of these (5.6%) contained a p53 mutation, as assessed by a sensitive yeast functional assay that detects mutations of the p53 mRNA between codons 52 and 364. These results indicate that p53 mutations are rare events in recurrent cervical carcinomas, and that somatic mutations of p53 do not provide cervical cancer cells with a selective growth advantage for recurrence.


Genes, p53/genetics , Mutation/genetics , Neoplasm Recurrence, Local/genetics , Uterine Cervical Neoplasms/genetics , Adult , Aged , Biopsy , DNA Mutational Analysis , Female , Genetic Predisposition to Disease , Genetic Testing , Humans , Middle Aged , Neoplasm Recurrence, Local/virology , Papillomaviridae/genetics , Papillomaviridae/isolation & purification , Polymerase Chain Reaction , RNA, Messenger/genetics , RNA, Messenger/metabolism , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/virology , Yeasts/genetics
15.
Zentralbl Gynakol ; 123(4): 179-85, 2001 Apr.
Article De | MEDLINE | ID: mdl-11370524

Certain molecularly defined types of human papillomaviruses (HPV) induce, by interaction with additional cofactors, cervical cancer. In comparison to infection with HPV, all risk factors identified to date are less important. In addition to HPV a not yet classified genetic predisposition is important. Identification of HPV in cervical smears is done by detection of viral DNA. PCR based methods have the highest specificity. Currently, first vaccination studies with therapeutic vaccines are performed and phase I/II trials for prophylactic vaccination show promising results.


Papillomaviridae/isolation & purification , Papillomavirus Infections/complications , Polymerase Chain Reaction/methods , Tumor Virus Infections/complications , Uterine Cervical Neoplasms/virology , Female , Genetic Predisposition to Disease , Germany/epidemiology , Humans , Immunotherapy, Active , Papillomavirus Infections/virology , Risk Factors , Tumor Virus Infections/virology , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/immunology , Uterine Cervical Neoplasms/therapy
16.
Genes Chromosomes Cancer ; 31(2): 196-8, 2001 Jun.
Article En | MEDLINE | ID: mdl-11319808

Telomerase activity can be detected in most human cancers and immortal cell lines. In contrast, the lack of telomerase activity in normal diploid fibroblasts has been correlated with progressive reduction of telomere lengths to critically short sizes followed by the cessation of cell division and the onset of senescence. Several investigators have provided evidence for the localization of a telomerase suppressor gene on chromosome 3. The aim of our study was to determine whether other chromosomes are involved in telomerase repression. Beside human chromosome 3 (serving as positive control), chromosomes 4, 6, and 11 were introduced into HeLa cells via microcell-mediated chromosome transfer. Telomerase activity from different hybrid cell lysates was determined at an early time point after fusion using a Telomerase ELISA kit. Strong repression of telomerase activity was only found in a subset of HeLa hybrids in which chromosome 3 or chromosome 4 had been introduced. Telomerase suppression induced by chromosome 3 or 4 transfer was paralleled by a high frequency (30% or 43%, respectively) of a senescent-like phenotype. Chromosomes 6 and 11, the functional loss of which is also implicated in cervical cancer, had no effect. These results indicate that normal human chromosomes 3 and 4 carry a gene or genes that suppress telomerase activity and induce cellular senescence in HeLa cells.


Chromosomes, Human, Pair 4/genetics , Gene Transfer Techniques , HeLa Cells/enzymology , Telomerase/biosynthesis , Cell Line, Transformed , Cellular Senescence/genetics , Chromosomes, Human, Pair 4/enzymology , Enzyme Activation/genetics , Enzyme Repression/genetics , Humans , Telomerase/metabolism , Tumor Cells, Cultured
17.
Int J Cancer ; 92(1): 9-17, 2001 Apr 01.
Article En | MEDLINE | ID: mdl-11279600

Human papillomavirus (HPV) genomes usually persist as episomal molecules in HPV associated preneoplastic lesions whereas they are frequently integrated into the host cell genome in HPV-related cancers cells. This suggests that malignant conversion of HPV-infected epithelia is linked to recombination of cellular and viral sequences. Due to technical limitations, precise sequence information on viral-cellular junctions were obtained only for few cell lines and primary lesions. In order to facilitate the molecular analysis of genomic HPV integration, we established a ligation-mediated PCR assay for the detection of integrated papillomavirus sequences (DIPS-PCR). DIPS-PCR was initially used to amplify genomic viral-cellular junctions from HPV-associated cervical cancer cell lines (C4-I, C4-II, SW756, and HeLa) and HPV-immortalized keratinocyte lines (HPKIA, HPKII). In addition to junctions already reported in public data bases, various new fusion fragments were identified. Subsequently, 22 different viral-cellular junctions were amplified from 17 cervical carcinomas and 1 vulval intraepithelial neoplasia (VIN III). Sequence analysis of each junction revealed that the viral E1 open reading frame (ORF) was fused to cellular sequences in 20 of 22 (91%) cases. Chromosomal integration loci mapped to chromosomes 1 (2n), 2 (3n), 7 (2n), 8 (3n), 10 (1n), 14 (5n), 16 (1n), 17 (2n), and mitochondrial DNA (1n), suggesting random distribution of chromosomal integration sites. Precise sequence information obtained by DIPS-PCR was further used to monitor the monoclonal origin of 4 cervical cancers, 1 case of recurrent premalignant lesions and 1 lymph node metastasis. Therefore, DIPS-PCR might allow efficient therapy control and prediction of relapse in patients with HPV-associated anogenital cancers.


DNA, Viral/analysis , Papillomaviridae/genetics , Polymerase Chain Reaction/methods , Uterine Cervical Neoplasms/virology , Virus Integration/genetics , Base Sequence , Cell Line, Transformed , DNA Ligases/metabolism , DNA, Mitochondrial/chemistry , DNA, Viral/chemistry , Female , HeLa Cells , Humans , Keratinocytes/virology , Molecular Sequence Data , Open Reading Frames , Recurrence , Sequence Analysis, DNA , Transfection , Tumor Cells, Cultured , Uterine Cervical Neoplasms/genetics , Vulvar Neoplasms/virology
18.
Int J Cancer ; 92(2): 285-93, 2001 Apr 15.
Article En | MEDLINE | ID: mdl-11291058

Cervical cancer has been shown to be highly associated with human papillomavirus (HPV) infection. The viral oncogenes E6 and E7 are constantly expressed by the tumor cells and are therefore targets for immunotherapy. In the present study we investigated the potential of HPV16 L1E7 chimeric virus-like particles (CVLP) to activate specific cytotoxic T lymphocytes in human blood donors. CVLP were expressed by recombinant baculovirus and purified. Direct incubation of freshly isolated peripheral blood lymphocytes (PBL) with CVLP resulted in induction of proliferation and growth of T cell lines. To enhance antigen presentation we also loaded dendritic cells with CVLP and used them to activate naive T cells. Growing cell lines were mainly CD3 positive (>95%) with a predominant CD4-positive and a minor CD8-positive component. Analysis of Tcell specificity was carried out by an interferon-gamma ELISpot assay. Dendritic cells pseudoinfected with CVLP or pulsed with human leukocyte antigen (HLA)-A*0201-restricted peptide E7(11-20) or with a newly identified HPV16 peptide L1(323-331) were used as stimulator cells. T cells responsive to CVLP were found in the cultures with frequencies of 0.5%-0.7%. Frequencies to peptides were around 0.1%. These T cells had cytolytic activity toward autologous B-lymphoblastic cell lines either pseudoinfected with CVLP or pulsed with HLA-A*0201-restricted peptides. They also lysed the HPV16- and HLA-A*0201-positive cervical cancer cell line CaSki, whereas HLA-A*0201-negative SiHa cells were not lysed. We conclude from our data that CVLP show promise for a therapeutic vaccine in patients with HPV16-positive cervical intraepithelial neoplasia lesions or cervical cancer.


Cancer Vaccines/therapeutic use , Capsid Proteins , Oncogene Proteins, Fusion/immunology , Oncogene Proteins, Viral/immunology , T-Lymphocytes, Cytotoxic/immunology , Uterine Cervical Dysplasia/therapy , Uterine Cervical Neoplasms/therapy , Antigens, Viral/genetics , Antigens, Viral/immunology , CD4-Positive T-Lymphocytes/immunology , Cell Line , Cells, Cultured , Cytotoxicity Tests, Immunologic , Dendritic Cells/immunology , Female , HLA-A Antigens/immunology , Humans , Interferon-gamma/biosynthesis , Lymphocyte Activation , Oncogene Proteins, Fusion/genetics , Oncogene Proteins, Viral/genetics , Papillomavirus E7 Proteins , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , T-Lymphocyte Subsets/immunology , Uterine Cervical Neoplasms/immunology , Uterine Cervical Neoplasms/virology , Virion/genetics , Virion/immunology , Uterine Cervical Dysplasia/immunology , Uterine Cervical Dysplasia/virology
19.
Int J Cancer ; 89(6): 529-34, 2000 Nov 20.
Article En | MEDLINE | ID: mdl-11102899

The validity of testing for high-risk types of human papillomavirus (HPV) in cervical cancer prevention programs is undetermined. We compared the performance on primary screening of HPV DNA testing, cytology and colposcopy in detecting cervical intra-epithelial neoplasia (CIN) grade 2 or 3 or cancer. A cohort of 4,761 women, median age 35 years, was screened by routine cytology, routine colposcopy and testing for high-risk HPV by a PCR-based method. Within an 8-month period, women with abnormal findings on cytology or screening colposcopy or in whom high-risk HPV types were detected were referred for colposcopy and biopsy. Women negative on all initial screening tests were followed by a second screening examination. To correct for work-up bias, the true prevalence of CIN 2 or 3 or cancer was estimated by projection from histologically verified subgroups. Cervical biopsies were taken in 364 women (7.6%), of whom 114 (2.4%) showed CIN 2 (n = 34) or CIN 3 (n = 71) or cancer (n = 9). High-risk HPV testing achieved bias-corrected performance measures of 89.4% sensitivity, 93.9% specificity, 35.8% positive predictive value and 99.6% negative predictive value. Bias-corrected rates of true- and false-positives by high-risk HPV testing compared to cytology (colposcopy) were about 4.5 (6.7) and 19.1 (7.4) times higher, respectively. The quality of routine cytology was controlled by computer-assisted review, and the observed number of true-positives more than doubled after adding automated review results. In middle-aged women, testing for high-risk HPV types, particularly when negative, may be used to increase the screening interval in programs for secondary prevention of cervical cancer.


Papillomaviridae , Uterine Cervical Dysplasia/virology , Uterine Cervical Neoplasms/virology , Adult , Age Factors , Aged , Colposcopy/economics , Cost-Benefit Analysis , Female , Humans , Mass Screening/economics , Middle Aged , Papillomavirus Infections/epidemiology , Papillomavirus Infections/virology , Prevalence , Sensitivity and Specificity , Tumor Virus Infections/epidemiology , Tumor Virus Infections/virology , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/pathology , Vaginal Smears/economics , Uterine Cervical Dysplasia/epidemiology , Uterine Cervical Dysplasia/pathology
20.
Ann N Y Acad Sci ; 919: 9-15, 2000.
Article En | MEDLINE | ID: mdl-11083092

An important aspect of the drug development process is prediction of efficacious and toxic side effects. Profiling of mRNA expression is a powerful approach to analyze the molecular phenotype of cells under various conditions, for example, in response to stimulation by compounds. We attempt to explore the approach of using expression profiling to identify patterns or fingerprints that are correlated with specific drug properties or behaviors. Identification of such expression patterns may also lead to revelation of the potential action mechanism of drugs and fingerprints indicative of certain drug efficacy or side effects. We describe here a strategy that was used to identify a set of genes whose differential expression pattern correlates with activation mode and target specificity of a specific group of drug compounds.


Drug-Related Side Effects and Adverse Reactions/genetics , Gene Expression Profiling , Oligonucleotide Array Sequence Analysis , Toxicity Tests/methods , Algorithms , Cell Line , Gene Expression/drug effects , Humans , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Signal Transduction/genetics , Software , Substrate Specificity/genetics
...